Returned Goods

This policy applies to Otsuka America Pharmaceutical, Inc. (OAPI) products purchased directly from OAPI. Only product purchased either directly from OAPI or from an OAPI-authorized distributor will be eligible for return. All products returned, whether eligible for credit or not, become the property of OAPI. 

A returned goods authorization (RGA) number must be obtained to return all OAPI products. Return authorizations expire sixty (60) days from the issue date. Products, including expired goods, returned without authorization will not be accepted for credit. 

Returning Procedure  

  • RGA requests pertaining to 

    ABILIFY® (aripiprazole) Tablets1 

    ABILIFY MYCITE® (aripiprazole tablets with sensor)2

    Replacement MYCITE® Patch 

    ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension3

    ABILIFY ASIMTUFII® (aripiprazole) for extended-release injectable suspension4

    DACOGEN® (decitabine) injection5

    IV BUSULFEX® (busulfan) injection6

    JYNARQUE® (tolvaptan) tablets7

    REXULTI® (brexpiprazole) tablets8

    SAMSCA® (tolvaptan) tablets9 

    NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) capsules10 

    including contact information can be faxed to (614) 652-0271 or emailed to GMB-SPS-ReturnRequests@cordlogistics.com. 

  • Returns must be accompanied by an itemized RGA form placed in the box with RA number written on the outside 

  • Upon physical receipt of the product being returned, provided that the return complies with the terms of this policy, OAPI will issue credit as described herein within 60 days of receipt 

 

Basis for Credit Reimbursement 

  • Credit will be issued on expired products not more than one (1) year after expiration and on products dated six (6) months or less prior to the expiration date 

  • Credit for returned product: 

  • For 

    ABILIFY MYCITE® (aripiprazole tablets with sensor)2

    ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension3

    ABILIFY ASIMTUFII® (aripiprazole) for extended-release injectable suspension4

    IV BUSULFEX® (busulfan) injection6

    JYNARQUE® (tolvaptan) tablets7

    REXULTI® (brexpiprazole) tablets8 

    SAMSCA® (tolvaptan) tablets9

    credit will be issued at the lower of: 

    1. the highest lot acquisition cost (i.e., lot list price net of any prompt pay or other discounts); or 

    2. any applicable contract price. 

  • For ABILIFY® tablets1, credit for returned product will be issued at current acquisition cost (where applicable, current contract price) as of the date the returned product is received at the designated return goods processor, less ten percent (10%) 

  • For NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) capsules10 credit for returned product will be issued at the highest lot acquisition cost less 5% or the applicable contract price, whichever is lower.

  • For opened packages of expired product otherwise eligible for reimbursement, the reimbursement value will be based upon exact count and not to exceed the original quantity on the label. For NUEDEXTA credit will be issued for full bottles only unless state law requires otherwise. For products that are packaged as vials or syringes credit will be issued if returned in the original, sealed, unopened containers.

  • Any credit issued by OAPI pursuant to this policy will be issued to authorized distributors of record (ADR), such as wholesalers, distributors, and other direct accounts. Indirect customers, such as retail and hospital pharmacies, will be issued credit memos through their ADR for eligible returned products. Indirect customers must also list their ADR information on the RGA. 

 

Non-Reimbursable Items 

  • Product not purchased either directly from OAPI or from an authorized distributor of record of OAPI will not be accepted for credit 

  • Product obtained illegally or via diverted means or acquired for the purpose of returning to OAPI for credit 

  • Repackaged product, non-legible lot/expiration-dated product, or altered original product containers (e.g., bearing a pharmacy label) 

  • Product acquired or purchased outside the United States and its territories will not be accepted for credit 

  • Product sold on a “non-returnable” basis; e.g., DACOGEN5 

  • Items purchased expressly as non-returnable 

  • Items dated more than six (6) months prior to the expiration date or more than one (1) year after the expiration date.

  • Items returned in other than the original retail trade packages. This includes, but is not limited to, items in packages marked “professional sample,” “professional package,” “clinical trial package,” or similar special labels 

  • Products acquired as free goods 

  • Overages (containers overpacked for return) 

  • Opened packages of the products that are packaged as vials or syringes, unless required by law. 

  • Items damaged by negligence, fire, water, smoke, or any other insurable event due to conditions beyond the reasonable control of OAPI; or sacrifice or bankruptcy sales 

  • Items for which OAPI cannot verify original proof of purchase 

 

Other Terms of Policy 

  • OAPI reserves the right to exclude products from this policy. In the event of product exclusion from this policy, a specific returned goods policy will be communicated for that product 

  • Buyer is to prepay all transportation and insurance charges. OAPI is not obligated to pay all, or any charges incurred by the buyer in processing or returning goods 

  • OAPI reserves the right to refuse returns shipped collect 

  • OAPI is not responsible for lost returns or returns damaged in shipment 

  • All products are returned with the understanding that they are subject to final review and evaluation by OAPI and will be processed in accordance with the most recent returned goods policy at the time the return is received 

  • OAPI reserves the right to modify the Returned Goods Policy without notice at any time. The current Returned Goods Policy will be made available here 

 

All returns for ABILIFY, ABILIFY MYCITE, Replacement MYCITE® Patch, ABILIFY MAINTENA, ABILIFY ASIMTUFII, IV BUSULFEX, JYNARQUE, REXULTI, SAMSCA and NUEDEXTA are to be made to:   

Otsuka America Pharmaceutical, Inc. 
Attn: Returns Department 
15 Ingram Blvd, Dock 43 
LaVergne, TN 37086 

 

1 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for ABILIFY® (aripiprazole) 

2 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for ABILIFY MYCITE® (aripiprazole tablets with sensor) 

3 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for ABILIFY MAINTENA® (aripiprazole) 

4 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for ABILIFY ASIMTUFII®

5 Please see FULL PRESCRIBING INFORMATION, for DACOGEN® (decitabine) 

6 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for IV BUSULFEX® (busulfan) 

7 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for JYNARQUE® (tolvaptan) (tablets) 

8 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for REXULTI® (brexpiprazole) 

9 Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING, for SAMSCA® (tolvaptan) 

10 Please see FULL PRESCRIBING INFORMATION for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate)